Regulatory expectations for more process control data in continuous manufacturing are helping drive adoption of advanced monitoring, modeling, and digital control approaches. A study by Korean researchers framed the shift around both technological advances in process analytical technologies and digital-twin style modeling, alongside guidance emphasizing validated process understanding and risk-based control. The article points to ICH Q13 as a key reference for expectations such as real-time monitoring and robust control strategies designed to keep product quality consistent in continuous operation. For manufacturers, the near-term takeaway is that innovation in continuous biomanufacturing is increasingly tied to regulators’ demand for model reliability, update evidence, and ongoing performance monitoring.